NCT00000226
Completed
Phase 2
Alternate-Day Buprenorphine Administration. Phase VII
ConditionsOpioid-Related Disorders
DrugsBuprenorphine
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Opioid-Related Disorders
- Sponsor
- National Institute on Drug Abuse (NIDA)
- Locations
- 1
- Primary Endpoint
- Opioid agonist effects
- Status
- Completed
- Last Updated
- 20 years ago
Overview
Brief Summary
The purpose of this study is to determine if four times a subjects daily maintenance dose will hold for 96 hours without changes in agonist and antagonist effects under open dosing conditions.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Opioid agonist effects
Pupil diameter
Drug use
Opioid withdrawal
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Alternate-Day Buprenorphine Administration. Phase VI - 7Opioid-Related DisordersNCT00000225National Institute on Drug Abuse (NIDA)
Completed
Phase 2
Alternate Day Buprenorphine Administration, Phase IX - 14Opioid-Related DisordersNCT00000232University of Vermont
Completed
Phase 1
Alternate-Day Buprenorphine Administration. Phase II - 4Opioid-Related DisordersNCT00000222National Institute on Drug Abuse (NIDA)
Completed
Phase 1
Alternate-Day Buprenorphine Administration. Phase I - 3Opioid-Related DisordersNCT00000221National Institute on Drug Abuse (NIDA)
Completed
Phase 2
Alternate-Day Buprenorphine Administration. Phase IV - 5Opioid-Related DisordersNCT00000223National Institute on Drug Abuse (NIDA)